Your browser doesn't support javascript.
loading
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani, Elisabetta; Di Guardo, Lorenza; Dugo, Matteo; Rigoletto, Sara; Tragni, Gabrina; Ruggeri, Roberta; Perrone, Federica; Tamborini, Elena; Gloghini, Annunziata; Arienti, Flavio; Vergani, Barbara; Deho, Paola; De Cecco, Loris; Vallacchi, Viviana; Frati, Paola; Shahaj, Eriomina; Villa, Antonello; Santinami, Mario; De Braud, Filippo; Rivoltini, Licia; Rodolfo, Monica.
Afiliação
  • Vergani E; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Di Guardo L; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Dugo M; Functional Genomics and Bioinformatics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Rigoletto S; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Tragni G; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Ruggeri R; Melanoma and Sarcoma Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Perrone F; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Tamborini E; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Gloghini A; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Arienti F; Immunohematology and Transfusion Medicine Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Vergani B; Consorzio MIA, Microscopy and Image Analysis, University of Milan Bicocca, Monza, Italy.
  • Deho P; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • De Cecco L; Functional Genomics and Bioinformatics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Vallacchi V; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Frati P; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Shahaj E; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Villa A; Consorzio MIA, Microscopy and Image Analysis, University of Milan Bicocca, Monza, Italy.
  • Santinami M; Melanoma and Sarcoma Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • De Braud F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Rivoltini L; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Rodolfo M; Immunotherapy Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Oncotarget ; 7(4): 4428-41, 2016 Jan 26.
Article em En | MEDLINE | ID: mdl-26684239
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Quimiocina CCL2 / Resistencia a Medicamentos Antineoplásicos / MicroRNAs / Indóis / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Quimiocina CCL2 / Resistencia a Medicamentos Antineoplásicos / MicroRNAs / Indóis / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Itália